IL2 and capillary leak syndrome: The response rate to high dose IL-2 is low (16%) but durable cures have been observed in approximately 6–10% of the patients that can tolerate the systemic toxicity (i.e. hypotension, capillary leak syndrome, sepsis and renal failure) [3,4].